Despite considerable evidence supporting the use of antiretroviral therapy (ART) for prevention of HIV and TB illness, death and transmission, only 37 percent of the 35 million people living with HIV were receiving it in 2013. This paper examines ongoing and planned global treatment as prevention studies and addresses research questions related to access and implementation.
Antiretroviral Treatment for Prevention of HIV and Tuberculosis
Facing Questions about Hormonal Contraceptives and HIV: What’s next in getting answers?
In this webinar we learned about and discussed proposed research to directly evaluate how different family planning methods might impact HIV risk.
Trial designs are actively being discussed and funding is being sought for such research—but there are many questions where advocates’ voices are needed: What should a trial look like? How can method mix (the range of available family planning options) be expanded for all women? What can be done to better integrate HIV and family planning in the meantime?
View the full webinar here
Ongoing and Planned PrEP Demonstration and Implementation Studies
This is a summary table of ongoing and planned global PrEP evaluation studies.
Global Investment in HIV Cure Research and Development in 2012
In 2013 the International AIDS Society HIV Cure Resource Tracking group joined with the HIV Vaccines and Microbicides Tracking Working Group to estimate global investments in HIV cure research and produce this short report.
Rectal Microbicides Video Facilitator’s Guide
This guide is meant to be used as a preparation tool for people leading community discussions, workshops, or recruitment sessions who will be showing the educational video. Background information on rectal microbicide research and the clinical trial process is included in the guide.
The GLAM Toolkit: Advocacy to improve access to safe, condom-compatible lubricant in Africa
The GLAM Toolkit: Advocacy to improve access to safe, condom-compatible lubricant in Africa” published by IRMA, amfAR and AVAC, provides background on the status of lubricant (lube) access in Africa and suggests potential strategies for civil society and government partners to secure and distribute sustainable supplies of safe, condom-compatible lube. Global Lube Access Mobilisation (GLAM) is a campaign of IRMA’s Project ARM (Africa for Rectal Microbicides) initiative.
MTN-017 Trial Launch Webinar
Be the Generation Bridge and International Rectal Microbicide Advocates (IRMA) hosted a webinar to mark the launch of MTN-017, the first-ever phase II safety study of a rectal microbicide. Ross D. Cranston, MD, of the University of Pittsburgh School of Medicine and co-leader of MTN-017, presented on the trial details, followed by Jim Pickett of IRMA who presented on the community engagement activities undertaken in support of the trial.
On the Map: Ensuring Africa’s Place in Rectal Microbicide Advocacy
IRMA hosted a strategy development meeting on 2-3 December 2011 in Addis Ababa, Ethiopia to develop an African rectal microbicide agenda that articulates research, advocacy, and community mobilization strategies. The strategy meeting brought together African stakeholders and allies representing a wide array of perspectives, experiences, and geographies to develop action steps for RM research and advocacy, specific to the African context.
Biomedical Prevention and Anal Sex
Cindra Feuer (AVAC) and Jim Pickett (IRMA) presented at AMSHeR’s 2-day Sexual Health and Rights Institute, which was held in December 2013 prior to ICASA 2013 in Cape Town, South Africa. The presentation included an update on biomedical ARV-based prevention and advocacy and rectal microbicide research and advocacy.
Africa Needs Safe and Accessible Lube Today; Rectal Microbicides Tomorrow
“Africa Needs Safe and Accessible Lube Today; Rectal Microbicides Tomorrow” was presented by Cindra Feuer (AVAC) and Jim Pickett (IRMA) at the AMSHeR pre-conference at ICASA 2013 in Cape Town, South Africa. The presentation includes a discussion on the WHO prevention guidelines; and updates on PrEP and rectal microbicides.